Episode
Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2
- Podcast
- Gynecologic Oncology Update
- Published
- Sep 14, 2026
- Duration seconds
- 1581
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/gynecologic-oncology-update-612940/episodes/low-grade-serous-ovarian-cancer-rapid-case-review-microlearning-activity-2/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/gynecologic-oncology-update-612940/low-grade-serous-ovarian-cancer-rapid-case-review-microlearning-activity-2.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03) Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15) Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49) CME information and select publications